Istaroxime, a potential anticancer drug in prostate cancer, exerts beneficial functional effects in healthy and diseased human myocardium

The current gold standard for prostate cancer treatment is androgen deprivation therapy and antiandrogenic agents. However, adverse cardiovascular events including heart failure can limit therapeutic use. Istaroxime, which combines Na(+)-K(+)-ATPase (NKA) inhibition with sarco/endoplasmic reticulum...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Oncotarget
Main Authors: Wallner, Markus, Khafaga, Mounir, Kolesnik, Ewald, Vafiadis, Aris, Schwantzer, Gerold, Eaton, Deborah M., Curcic, Pero, Köstenberger, Martin, Knez, Igor, Rainer, Peter P., Pichler, Martin, Pieske, Burkert, Von Lewinski, Dirk
Formato: Artigo
Idioma:Inglês
Publicado: Impact Journals LLC 2017
Assuntos:
Research Paper
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5564766/
https://ncbi.nlm.nih.gov/pubmed/28514771
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.17540
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares